What Has Been the Growth of the Hidradenitis Suppurativa Market So Far?
The hidradenitis suppurativa market has seen considerable growth due to a variety of factors.
•The market for hidradenitis suppurativa has witnessed robust growth in the previous years. The market worth will increase from $1.16 billion in 2024 to $1.25 billion in 2025, experiencing a compound annual growth rate (CAGR) of 7.8%.
The surge in growth during the historic period can be credited to factors such as enhanced awareness of diagnosis, limited available treatments, progress in dermatology, increasing disease incidence, and initiatives advocating for patients.
What Are the Future Growth Projections for the Hidradenitis Suppurativa Market?
The hidradenitis suppurativa market is expected to maintain its strong growth trajectory in upcoming years.
• The market for hidradenitis suppurativa is poised to experience a significant increase in the following years, swelling to a value of $1.63 billion by 2029, progressing at a CAGR of 7.0%.
The projected growth during this period could be a result of the advancement in biologic treatments, the precision of medical methodologies, the broadening of clinical trials, international initiatives and financial aid, coupled with backing from healthcare policies. The upcoming period anticipates trends such as advanced immunomodulatory treatments, telemedicine in conjunction with remote patient monitoring, patient-focused healthcare, less invasive surgical procedures, and individualized advice on lifestyle.
What Are The Core Factors Supporting Growth In The Hidradenitis Suppurativa Market?
The escalation in the occurrence of skin conditions is propelling the advancement of the hidradenitis suppurativa market. Skin conditions encompass a broad array of skin issues, which include bacteria-invoked infections, virus-induced infections, fungus-based infections, allergy-related symptoms, skin cancers, and parasite-related diseases. Hidradenitis suppurativa (HS), a chronic and intense skin ailment, stimulates the inception of new commodities and aids for its control owing to heightened consciousness, precise diagnostics, an expanding pool of patients, and progress in research. For instance, in January 2024, the American Cancer Society, a U.S. non-profit institution committed to eradicating cancer, predicts there'll be 108,270 diagnosed cases of skin cancer, a 3.2% rise from the 104,930 cases noted in 2023. Thus, escalating occurrences of skin conditions are fueling the advancement of the hidradenitis suppurativa market.
What Are The Major Segments Within The Global Hidradenitis Suppurativa Market?
The hidradenitis suppurativa market covered in this report is segmented –
1) By Skin Condition: Folliculitis, Pimples, Boils, Deep-Acne
2) By Product: Tablet, Intravenous (IV) Injection
3) By Route Of Administration: Oral, Parenteral
4) By Treatment: Medications, Surgery, Photodynamic Therapy (PDT), Laser Treatment, Other Treatments
5) By End User: Hospital, Specialty Clinic, Homecare, Other End Users
Subsegments:
1) By Folliculitis: Acute Folliculitis, Chronic Folliculitis
2) By Pimples: Non-Inflammatory Pimples, Inflammatory Pimples
3) By Boils: Single Boil, Recurrent Boils
4) By Deep-Acne: Cysts, Nodules
Pre-Book The Hidradenitis Suppurativa Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Trends Are Expected To Transform The Hidradenitis Suppurativa Market?
The increasing use of biologics is a prominent trend within the hidradenitis suppurativa market. Top companies within the market are enhancing their standing through significant investment in research and development, which has contributed to the approval of new biologic therapies for hidradenitis suppurativa. To illustrate, in June 2023, the European regulatory authority sanctioned Switzerland-based Novartis AG to produce Cosentyx for hidradenitis suppurativa. Cosentyx is the first wholly human biologic that effectively inhibits interleukin-17A, a key cytokine related to hidradenitis suppurative disease. With over 14 years of clinical research behind it, Cosentyx has built a strong reputation as a trusted treatment.
Who Are the Key Players in the Hidradenitis Suppurativa Market?
Major companies operating in the hidradenitis suppurativa market include:
• Pfizer Inc.
• Johnson & Johnson
• AbbVie Inc.
• Novartis AG
• Eli Lilly and Co Ltd.
• UCB S.A.
• Leo Pharma A/S
• Almirall S.A.
• Acelyrin Inc.
• AnaptysBio Inc.
• Arcutis Biotherapeutics Inc.
• Otsuka Pharmaceutical Co. Ltd.
• Yamo Pharmaceuticals
• Bayer AG
• AstraZeneca plc
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma
• Chemocentryx
• Priovant Therapeutics
• Aristea Therapeutics
• Samsung Bioepis
• Organon
• Union Therapeutics
• Revance Therapeutics
• Dermavant Sciences
• Dermira Inc.
• MedImmune LLC
• Taro Pharmaceutical Industries Ltd.
• Immunic Inc.
What Is The Most Dominant Region In The Hidradenitis Suppurativa Market?
North America was the largest region in the hidradenitis suppurativa market in 2024. The regions covered in the hidradenitis suppurativa market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
